Vyzulta (latanoprostene bunod)
Glaucoma / Ocular Hypertension
ApprovedCommercial
Key Facts
About Bausch Health
Bausch Health Companies Inc. is a multinational company dedicated to improving people's lives through its portfolio of pharmaceutical, medical device, and over-the-counter products. Its strategy revolves around its core therapeutic areas, leveraging a mix of in-house R&D and strategic acquisitions, most notably the Bausch + Lomb eye health business. The company is executing a turnaround plan focused on debt reduction, portfolio optimization, and growth in key segments like gastroenterology and aesthetics to drive long-term shareholder value.
View full company profileTherapeutic Areas
Other Glaucoma / Ocular Hypertension Drugs
| Drug | Company | Phase |
|---|---|---|
| SE-1003 | Santen Pharmaceutical | Phase 2 |
| Tapros® (tafluprost) | Santen Pharmaceutical | Approved |
| Mirac® (ripasudil) | Santen Pharmaceutical | Approved |
| Catioprost® | Santen Pharmaceutical | Approved |
| OTX-TIC (travoprost insert) | Ocular Therapeutix | Phase 1 |